Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.


K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.

Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM.

Mol Oncol. 2017 Sep;11(9):1130-1142. doi: 10.1002/1878-0261.12078. Epub 2017 Jun 14.


Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.

McGee SR, Tibiche C, Trifiro M, Wang E.

Genomics Proteomics Bioinformatics. 2017 Apr;15(2):121-129. doi: 10.1016/j.gpb.2017.02.002. Epub 2017 Apr 7.


TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L.

Oncol Rep. 2017 Apr;37(4):2215-2226. doi: 10.3892/or.2017.5494. Epub 2017 Mar 8.


A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.

de Melo AC, Paulino E, Garces ÁH.

Oxid Med Cell Longev. 2017;2017:4809751. doi: 10.1155/2017/4809751. Epub 2017 Feb 13. Review.


Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.

Jia F, Teer JK, Knepper TC, Lee JK, Zhou HH, He YJ, McLeod HL.

Mol Diagn Ther. 2017 Apr;21(2):179-185. doi: 10.1007/s40291-016-0250-z.


Functional exploration of colorectal cancer genomes using Drosophila.

Bangi E, Murgia C, Teague AG, Sansom OJ, Cagan RL.

Nat Commun. 2016 Nov 29;7:13615. doi: 10.1038/ncomms13615.


Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T.

World J Gastroenterol. 2016 Jul 28;22(28):6345-61. doi: 10.3748/wjg.v22.i28.6345. Review.


Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.

Fernandes MS, Melo S, Velho S, Carneiro P, Carneiro F, Seruca R.

Oncotarget. 2016 Oct 18;7(42):68546-68558. doi: 10.18632/oncotarget.11843.


Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L.

Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369. Epub 2016 Jul 6. Review.


BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells.

He K, Chen D, Ruan H, Li X, Tong J, Xu X, Zhang L, Yu J.

Oncotarget. 2016 Jul 26;7(30):47699-47710. doi: 10.18632/oncotarget.10277.


Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.

Watari K, Nishitani A, Shibata T, Noda M, Kawahara A, Akiba J, Murakami Y, Yano H, Kuwano M, Ono M.

Oncotarget. 2016 Jul 26;7(30):47403-47417. doi: 10.18632/oncotarget.10161.


Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.


PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.

Alberobello AT, Wang Y, Beerkens FJ, Conforti F, McCutcheon JN, Rao G, Raffeld M, Liu J, Rahhal R, Zhang YW, Giaccone G.

J Thorac Oncol. 2016 Aug;11(8):1345-1356. doi: 10.1016/j.jtho.2016.04.013. Epub 2016 Apr 24.


Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.

Zhang N, Liu H, Yue G, Zhang Y, You J, Wang H.

PLoS One. 2016 Apr 14;11(4):e0153546. doi: 10.1371/journal.pone.0153546. eCollection 2016. Erratum in: PLoS One. 2016 Oct 18;11(10 ):e0165251.


Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.

Faggiano A, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, Giordano EA, Guarnotta V, Logoluso FA, Messina E, Nicastro V, Nuzzo V, Sciaraffia M, Colao A.

Oncologist. 2016 Jul;21(7):875-86. doi: 10.1634/theoncologist.2015-0420. Epub 2016 Apr 6. Review.


Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

Josephs DH, Sarker D.

Transl Oncogenomics. 2016 Feb 21;7(Suppl 1):33-49. doi: 10.4137/TOG.S30529. eCollection 2015. Review.


Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC.

Oncotarget. 2016 Mar 1;7(9):10547-56. doi: 10.18632/oncotarget.7234.


Cap dependent translation contributes to resistance of myeloma cells to bortezomib.

Mancino M, Grosso S, Terragna C, Borsi E, Cavo M, Biffo S.

Translation (Austin). 2013 Nov 18;1(2):e27245. doi: 10.4161/trla.27245. eCollection 2013.


Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide.

Karnan S, Ota A, Konishi Y, Wahiduzzaman M, Hosokawa Y, Konishi H.

Nucleic Acids Res. 2016 Apr 7;44(6):e54. doi: 10.1093/nar/gkv1338. Epub 2015 Dec 10.

Supplemental Content

Support Center